Modulating the transcriptional landscape of SARS-CoV-2 as an effective method for developing antiviral compounds
Hoagland, D. A.; Clarke, D. J. B.; Moeller, R.; Han, Y.; Yang, L.; Wojciechowicz, M. L.; Lachmann, A.; Oguntuyo, K. Y.; Stevens, C.; Lee, B.; Chen, S.; Ma'ayan, A.; tenOever, B. R.
Show abstract
To interfere with the biology of SARS-CoV-2, the virus responsible for the COVID-19 pandemic, we focused on restoring the transcriptional response induced by infection. Utilizing expression patterns of SARS-CoV-2-infected cells, we identified a region in gene expression space that was unique to virus infection and inversely proportional to the transcriptional footprint of known compounds characterized in the Library of Integrated Network-based Cellular Signatures. Here we demonstrate the successful identification of compounds that display efficacy in blocking SARS-CoV-2 replication based on their ability to counteract the virus-induced transcriptional landscape. These compounds were found to potently reduce viral load despite having no impact on viral entry or modulation of the host antiviral response in the absence of virus. RNA-Seq profiling implicated the induction of the cholesterol biosynthesis pathway as the underlying mechanism of inhibition and suggested that targeting this aspect of host biology may significantly reduce SARS-CoV-2 viral load.
Matching journals
The top 9 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
- The protease inhibitor Nirmatrelvir synergizes with inhibitors of GRP78 to suppress SARS-CoV-2 replication 96%
- The rocaglate CR-31-B (-) inhibits SARS-CoV-2 replication at non-cytotoxic, low nanomolar concentrations in vitro and ex vivo 95%
- The α-dystroglycan N-terminus is a broad-spectrum antiviral agent against SARS-CoV-2 and enveloped viruses 94%
Similar papers in this journal
- 2-Thiouridine is a broad-spectrum antiviral nucleoside analogue against positive-strand RNA viruses 94%
- Mechanistic Insights into Dengue Virus Inhibition by a Clinical Trial Compound NITD-688 93%
- Inhibition of tumor growth by a novel engineered chimeric toxin that cleaves activated mutant and wild-type RAS 93%
Similar papers in this journal
Similar papers in this journal
- Oral Hsp90 inhibitor, SNX-5422, attenuates SARS-CoV-2 replication and dampens inflammation in airway cells. 96%
- Identification of novel antiviral drug candidates using an optimized SARS-CoV-2 phenotypic screening platform 96%
- VE607 Stabilizes SARS-CoV-2 Spike In the "RBD-up" Conformation and Inhibits Viral Entry 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.